Ibuprofen Kabi (Ibuprofen)

The drug works by non‑selectively inhibiting the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which reduces the synthesis of prostaglandins. Lower prostaglandin levels diminish inflammation, pain signaling, and fever generation, delivering the characteristic analgesic, antipyretic, and anti‑inflammatory actions of ibuprofen.

The specific dose and infusion rate are determined by the prescribing clinician based on the patient’s condition, weight, renal function, and other clinical factors. Healthcare professionals follow local guidelines and product labeling to individualise therapy for each patient.

Safety data for intravenous ibuprofen during pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider after a thorough risk‑benefit assessment.

To place an order, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Compared with other intravenous NSAIDs such as ketorolac, ibuprofen offers a similar analgesic profile but may have a slightly lower risk of renal toxicity at equivalent doses. Its longer half‑life can allow less frequent dosing, while ketorolac is often chosen for very short‑term, high‑intensity pain control. Choice depends on patient factors and institutional protocols.

Ibuprofen Kabi must be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. If a short period at controlled room temperature is unavoidable, follow the manufacturer’s guidance on stability before use.

The product is supplied as a sterile intravenous solution. It is typically diluted in a compatible infusion fluid and administered over a prescribed period, often 15‑30 minutes, under aseptic conditions. Administration is performed by qualified healthcare personnel in a clinical setting.

Serious adverse events include severe gastrointestinal bleeding, anaphylactic or severe allergic reactions, acute renal failure, and cardiovascular thrombotic events such as myocardial infarction or stroke. Patients should be monitored closely for signs of bleeding, renal dysfunction, or hypersensitivity during and after infusion.

Contraindications include known hypersensitivity to ibuprofen or other NSAIDs, active gastrointestinal ulcer or bleeding, severe renal impairment, uncontrolled hypertension, and patients with a history of cardiovascular thrombotic disease where NSAID use is discouraged. Clinicians should evaluate each patient’s medical history before initiating therapy.